Skip to content

AptarGroup ATR Pharma — Goodwill, Acquired During Period

Similar metrics at other companies

Cardinal Health logo
CAHPharmaceutical and Specialty Solutions — Goodwill, Acquired During Period
$1.9B+149%
Baxter International logo
BAXPharmaceuticals — Goodwill
$569M+2.2%
Johnson & Johnson logo
JNJPharmaceutical — Goodwill, related to acquisitions
$0
Labcorp Holdings logo
LHBiopharma Laboratory Services — Goodwill acquired, excluding measurement period adjustments
$0
Johnson & Johnson logo
JNJPharmaceutical — Goodwill (Note 3)
$14.81B+35.8%
Marathon Petroleum logo
MPCRefining And Marketing — Goodwill, Acquired During Period
$0

Other financials

Income statement

See full
Revenue$982.9M+10.8%
Gross profit$351.9M+4.6%
Operating income$107.5M-5.2%
Net income$72.7M-7.8%
EPS (diluted)$1.12-4.3%

Balance sheet

See full
Cash & equivalents$225.0M+78.8%
Total debt$1.4B+32.7%
Total equity$2.6B+3.6%
Total assets$5.1B+12.6%

Cash flow

See full
Operating cash flow$118.7M+43.5%
CapEx$65.4M+15.0%
Free cash flow$53.3M+106%

Valuation

See full
Market cap$7.68B-17.9%
Enterprise value$8.89B-13.9%
P/E19.9×-5.4×
P/S-0.6×

Profitability

See full
Gross margin36.7%-1.6pp
Operating margin12.8%-1.2pp
Net margin10%-0.4pp
FCF margin8.4%-2.1pp

Returns & leverage

See full
Return on equity15%-0.2pp
Debt / equity0.5×+0.1×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: AptarGroup’s 10-K, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's pharma — goodwill, acquired during period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AptarGroup's pharma — goodwill, acquired during period?
AptarGroup (ATR) reported pharma — goodwill, acquired during period of $2.35M in Q4 2025.
What does pharma — goodwill, acquired during period mean?
The premium paid over the fair value of net identifiable assets when acquiring businesses specifically integrated into the Pharma segment. This reflects the value of intangible synergies, market access, and intellectual property gained through M&A activity.